Revolution Medicines to Unveil Pancreatic Cancer Data at ESMO Congress
Event summary
- Revolution Medicines will present four clinical data sets at the ESMO Gastrointestinal Cancers Congress 2026, including two oral presentations and two posters.
- Phase 1/2 trial results for zoldonrasib in combination with chemotherapy and daraxonrasib will be highlighted for metastatic pancreatic cancer.
- Two Phase 3 trials-in-progress posters will detail RASolute 303 (daraxonrasib monotherapy/combination) and RASolute 304 (adjuvant daraxonrasib).
- Presentations scheduled for July 2–3, 2026 in Munich, Germany.
The big picture
Revolution Medicines is advancing its pipeline of RAS(ON) inhibitors, targeting a critical unmet need in pancreatic cancer treatment. The upcoming data presentations could validate its combination therapy approach, potentially reshaping treatment paradigms for RAS-addicted cancers. Success here would strengthen Revolution's position against competitors developing similar targeted therapies.
What we're watching
- Clinical Efficacy
- How the combination regimens of zoldonrasib and daraxonrasib perform against metastatic pancreatic cancer in Phase 1/2 trials.
- Regulatory Pathway
- Whether the Phase 3 trial designs for RASolute 303 and 304 position Revolution Medicines for potential approvals.
- Competitive Positioning
- The pace at which Revolution Medicines can differentiate its RAS(ON) inhibitors in the crowded oncology market.